FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/27/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. NVDA
9. FDXF
10. RKLB

Go back to FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis

Valeant (VRX) Pipeline Developments 'Positive', But In-Line with Expectations - BMO Capital

July 20, 2016 7:40 AM EDT

BMO Capital analyst Gary Nachman weighed in on Valeant Pharmaceuticals (NYSE: VRX) after an FDA advisory panel resulted in unanimous support for the approval of brodalumab for the treatment of moderate to severe plaque psoriasis. However, the majority of the panel (78%) supported additional risk... More